Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer
Open Access
- 11 July 2022
- journal article
- review article
- Published by Bioscientifica in Endocrine Oncology
- Vol. 2 (1) , R78-R89
Abstract
Hyponatraemia is a common electrolyte abnormality seen in a wide range of oncological and haematological malignancies and confers poor performance status, prolonged hospital admission and reduced overall survival, in patients with cancer. Syndrome of inappropriate antidiuresis (SIAD) is the commonest cause of hyponatraemia in malignancy and is characterised by clinical euvolaemia, low plasma osmolality and concentrated urine, with normal renal, adrenal and thyroid function. Causes of SIAD include ectopic production of vasopressin (AVP) from an underlying tumour, cancer treatments, nausea and pain. Cortisol deficiency is an important differential in the assessment of hyponatraemia, as it has an identical biochemical pattern to SIAD and is easily treatable. This is particularly relevant with the increasing use of immune checkpoint inhibitors, which can cause hypophysitis and adrenalitis, leading to cortisol deficiency. Guidelines on the management of acute, symptomatic hyponatraemia recommend 100 mL bolus of 3% saline with careful monitoring of the serum sodium to prevent overcorrection. In cases of chronic hyponatraemia, fluid restriction is recommended as first-line treatment; however, this is frequently not feasible in patients with cancer and has been shown to have limited efficacy. Vasopressin-2 receptor antagonists (vaptans) may be preferable, as they effectively increase sodium levels in SIAD and do not require fluid restriction. Active management of hyponatraemia is increasingly recognised as an important component of oncological management; correction of hyponatraemia is associated with shorter hospital stay and prolonged survival. The awareness of the impact of hyponatraemia and the positive benefits of active restoration of normonatraemia remain challenging in oncology.Keywords
This publication has 87 references indexed in Scilit:
- A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptanBMC Pulmonary Medicine, 2013
- The Incidence of Hyponatraemia and Its Effect on the ECOG Performance Status among Lung Cancer PatientsJournal of Clinical and Diagnostic Research, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Diagnosis and Management of Hyponatremia in Cancer PatientsThe Oncologist, 2012
- Efficacy and Tolerance of Urea Compared with Vaptans for Long-Term Treatment of Patients with SIADHClinical Journal of the American Society of Nephrology, 2012
- 2 Differential diagnosis of hyponatraemiaBest Practice & Research Clinical Endocrinology & Metabolism, 2012
- Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretionEuropean Journal of Endocrinology, 2011
- Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinomaBritish Journal of Cancer, 2010
- Lung cancer at a university hospital in Saudi Arabia: A four-year prospective study of clinical, pathological, radiological, bronchoscopic, and biochemical parametersAnnals of Thoracic Medicine, 2010
- Experience With Electrolyte Levels After Craniotomy for Pediatric Brain TumorsJournal of Pediatric Oncology Nursing, 2009